Associated Papers
Transcriptome-based screening in TARDBP/TDP-43 knock-in motor neurons identifies the NEDD8-activating enzyme inhibitor MLN4924.
Lépine S et al.
Scientific Reports, 2025
Pathogenic TDP-43 in amyotrophic lateral sclerosis.
Chong ZZ et al.
Drug Discovery Today, 2025
Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-43 proteinopathy.
Balendra R et al.
The Lancet. Neurology, 2025
40252666 (PubMed )
Supplement: EMS205435-supplement-Supplementary_table_1.pdf
Proteome Aggregation in Cells Derived from Amyotrophic Lateral Sclerosis Patients for Personalized Drug Evaluation.
Pérez de la Lastra Aranda C et al.
Acs Chemical Neuroscience, 2024
Molecular pathology, developmental changes and synaptic dysfunction in (pre-) symptomatic human C9ORF72-ALS/FTD cerebral organoids.
van der Geest AT et al.
Acta Neuropathologica Communications, 2024
Dynactin-1 mediates rescue of impaired axonal transport due to reduced mitochondrial bioenergetics in amyotrophic lateral sclerosis motor neurons.
Dafinca R et al.
Brain Communications, 2024
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis.
Lépine S et al.
Translational Neurodegeneration, 2022
Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.
Wood A et al.
International Journal of Molecular Sciences, 2021
Impairment of Mitochondrial Calcium Buffering Links Mutations in C9ORF72 and TARDBP in iPS-Derived Motor Neurons from Patients with ALS/FTD.
Dafinca R et al.
Stem Cell Reports, 2020
Select a paper to view details